PerkinElmer Completes $600M Caliper Acquisition | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – PerkinElmer today completed its acquisition of Caliper Life Sciences for $10.50 per share, valuing the deal at around $600 million.

The purchase, announced in September, provides PerkinElmer with Caliper's portfolio of imaging, microfluidics, automation, and sample preparation platforms and technologies and is expected to extend PerkinElmer's reach into the life sciences research space.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: new chromatin imaging approach, and more.

University of Wisconsin researchers uncover a mutation linked to Mauriac syndrome, which affects some children with type 1 diabetes.

Theranos has hired executives to oversee compliance and regulatory issues, the Wall Street Journal reports.

Chinese researchers to embark on a trial using a CRISPR/Cas9-based immunotherapy next month, Nature News reports.